Extramedullary hematopoiesis occurs in which type of leukemias, the one with immature blasts or the one with mature cells?
Reading File
Finding Sources
Searching the Web
extramedullary hematopoiesis chronic vs acute leukemia
Finding Sources
Reading File
The answer is clear. Here's a concise explanation:
Extramedullary hematopoiesis occurs in chronic leukemias (the ones with mature cells), specifically in myeloproliferative neoplasms (MPNs).
Why chronic/mature-cell leukemias?
In myeloproliferative neoplasms — the chronic leukemias characterized by overproduction of mature or maturing myeloid elements — the bone marrow is progressively replaced by fibrosis (myelofibrosis). As the marrow can no longer sustain adequate blood cell production, the liver, spleen, and lymph nodes revert to their fetal role and take over hematopoiesis. This is extramedullary hematopoiesis (EMH).
Classic examples:
- Chronic Myeloid Leukemia (CML) — BCR-ABL driven
- Primary Myelofibrosis — the MPN most notorious for massive splenomegaly due to EMH
- Polycythemia Vera (PV) — can develop a "spent phase" with myelofibrosis and secondary EMH
- Essential Thrombocythemia — less commonly
As Robbins Pathology summarizes: "Myeloid tumors in which production of formed myeloid elements is initially increased, leading to high blood counts and extramedullary hematopoiesis... All can transform to acute leukemia and to a spent phase of marrow fibrosis associated with anemia, thrombocytopenia, and splenomegaly."
Why NOT in acute leukemias (immature blasts)?
In acute leukemias (AML, ALL), the bone marrow is packed with immature, non-functional blasts that cannot differentiate. The problem is blast accumulation and suppression of normal hematopoiesis — not marrow fibrosis. There is no drive for the spleen/liver to compensate, so EMH is not a feature. (Note: leukemia cutis/extramedullary infiltrates of blasts can occur in acute leukemia, but that is leukemic infiltration, not hematopoiesis.)
In summary: Extramedullary hematopoiesis → chronic myeloproliferative neoplasms (mature cells) → driven by progressive myelofibrosis replacing normal marrow.
- Robbins, Cotran & Kumar Pathologic Basis of Disease — Myeloproliferative Neoplasms section
- Harrison's Principles of Internal Medicine 22E — Ch. 108, Polycythemia Vera and Other Myeloproliferative Neoplasms
In both the cases marrow can't produce effective cells, then why no EMH in acute leukemias alone
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
The textbooks confirm the key mechanism. Here is the complete pathophysiological answer:
Why No EMH in Acute Leukemia?
You are right that in both cases the marrow fails to produce functional blood cells. But the mechanism of failure is fundamentally different, and that difference is everything.
The Core Distinction: What is still in the marrow
| Acute Leukemia | Chronic MPN → Myelofibrosis | |
|---|---|---|
| Marrow content | Packed with blasts (cells still physically present) | Progressively replaced by fibrous tissue (cells physically displaced) |
| Hematopoietic stem cells (HSCs) | Trapped/suppressed in place | Physically expelled into circulation |
| HSC location | Still in the marrow (just non-functional) | Circulating, free to engraft elsewhere |
| Extramedullary niche | No stem cells arrive to seed it | Stem cells arrive and engraft |
The Mechanism of EMH
EMH requires two things:
- Circulating HSCs that escape the marrow
- Available niches in the spleen/liver to receive and support them
In myelofibrosis (the end-stage of MPNs), fibrosis physically crowds out and displaces neoplastic HSCs into the bloodstream. As Robbins states: "As marrow fibrosis progresses, circulating neoplastic HSCs take up residence in niches in secondary hematopoietic organs, such as the spleen, the liver, and the lymph nodes, leading to the appearance of extramedullary hematopoiesis."
Similarly, Andrews' Diseases of the Skin notes: "Blast cells and committed stem cells escape the marrow in large numbers, enter the circulation, and form tumors of the same atypical clone in other organs."
In acute leukemia, the marrow is not fibrotic — it is filled with blasts. The HSCs are suppressed and crowded out functionally, but they are not physically expelled. They remain stuck in the marrow microenvironment. Without HSC mobilization into the blood, there are no stem cells to seed extramedullary sites, so EMH cannot occur.
A Useful Analogy
Think of it this way:
- Acute leukemia = a factory floor so crowded with broken machines that workers can't do their jobs — but the workers are still inside.
- Myelofibrosis = the factory floor itself is torn up and demolished — the workers are forced out and have to set up a new factory elsewhere (spleen, liver).
EMH is the "new factory." It only gets built when workers (HSCs) are physically evicted — not when they're merely overwhelmed inside.
One More Point: Time Course
Acute leukemias develop over days to weeks. There simply isn't time for extramedullary niches to be established. MPNs evolve over years to decades, allowing gradual colonization of secondary hematopoietic organs.
- Robbins, Cotran & Kumar Pathologic Basis of Disease — Pathogenesis, Myeloproliferative Neoplasms
- Harrison's Principles of Internal Medicine 22E — Myelophthisic Anemias; MPN Complications
Extramedullary niches
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Great source material. Here is a thorough breakdown of niches — normal and extramedullary.
The Hematopoietic Stem Cell Niche
A niche is a specialized microenvironment that does two things simultaneously: nurtures stem cells (provides survival signals, growth factors, oxygen) and constrains them (regulates their number, prevents runaway proliferation). Harrison's describes it as "acting as both a nutritive and constraining home."
The Normal Bone Marrow Niche
Located in the perivascular space, especially near trabecular bone. Its key cellular components:
| Component | Role |
|---|---|
| Mesenchymal stromal cells | Secrete kit ligand and CXCL12 (SDF-1) — critical HSC survival/retention signals |
| CXCL12-abundant reticular (CAR) cells | Major source of CXCL12, anchor HSCs via CXCR4 receptor |
| Endothelial cells | Form sinusoids; co-produce kit ligand and CXCL12 |
| Osteoblasts | Line the endosteal surface; regulate HSC quiescence |
| Megakaryocytes | Promote HSC quiescence via TGF-β |
| Sympathetic neurons / Schwann cells | Regulate HSC mobilization rhythmically |
| Extracellular matrix | Osteopontin, heparan sulfates — anchor and modulate HSC behavior |
The CXCR4/CXCL12 axis is the master retention signal. When this is disrupted (e.g., by G-CSF or plerixafor clinically), HSCs are released into circulation — this is exactly what happens pathologically in myelofibrosis.
How HSCs Navigate to a Niche (Homing)
When HSCs circulate, they home to niches through a stepwise process:
- Rolling — CD162/CD44 on HSCs bind P- and E-selectin on endothelium
- Firm adhesion — VLA-4 on HSCs engages VCAM-1 on endothelium
- Transmigration — CXCR4 on HSCs follows the CXCL12 gradient into the marrow
This same mechanism applies when expelled HSCs home to the spleen and liver in myelofibrosis — those organs retain fetal hematopoietic niches that can be reactivated.
Why Spleen and Liver? — The Fetal Niche Explanation
This is the key insight. The spleen and liver are not random sites — they were the original hematopoietic organs during fetal life:
| Developmental Stage | Primary Site |
|---|---|
| ~2 weeks (mesoblastic phase) | Yolk sac |
| 2nd month → mid-gestation | Fetal liver (major site) |
| 3rd trimester → birth | Bone marrow (takes over permanently) |
| Spleen | Minor role alongside liver in fetal life |
After birth, these fetal niches go dormant — but their stromal infrastructure (sinusoids, stromal cells, CXCL12-producing cells) persists. When HSCs are physically expelled from a fibrosed marrow and circulate, they encounter these latent niches in the spleen and liver, re-engage via CXCR4/CXCL12 homing, and reactivate hematopoiesis. This is extramedullary hematopoiesis — essentially a reversion to the fetal program.
Why Spleen Gets Massively Enlarged
The spleen's red pulp sinusoids are particularly receptive — they have a fenestrated architecture similar to marrow sinusoids, and the organ is already designed to process blood cells. Engrafting HSCs proliferate here, causing massive splenomegaly (spleens can exceed 2800 g vs. a normal 150–200 g in myelofibrosis).
Summary
-
The bone marrow niche = perivascular, endosteal, CXCL12-rich microenvironment that retains HSCs
-
In myelofibrosis, fibrosis destroys this niche → CXCL12/CXCR4 retention fails → HSCs spill out
-
Spleen and liver have latent fetal niches that can re-engraft circulating HSCs
-
EMH is the reactivation of these fetal niches — not random seeding of any organ
-
Harrison's Principles of Internal Medicine 22E — HSC Microenvironment, HSC Mobility sections
-
Goldman-Cecil Medicine — Hematopoietic stem and progenitor cells
Engraft
Engraftment means a stem cell has successfully settled into a niche, established itself, and begun producing daughter cells — essentially, it has "taken root."
Here's the step-by-step of what happens:
1. Circulation
The HSC is floating freely in the bloodstream. At this point it is not producing anything — it is just a passenger.
2. Homing (Finding the Niche)
As the HSC passes through the sinusoids of the spleen or liver:
- It slows down (rolling) via selectin interactions
- It sticks firmly to the endothelial wall via VLA-4/VCAM-1
- It follows the CXCL12 gradient (secreted by stromal cells in the niche) through the vessel wall into the tissue
3. Lodging
The HSC physically parks itself next to the stromal cells — mesenchymal cells, CAR cells, endothelial cells — that make up the niche. It receives survival signals: kit ligand, CXCL12, direct cell-to-cell contact.
4. Self-renewal + Differentiation
Once lodged and receiving niche signals:
- Some daughter cells stay as HSCs (self-renewal — maintains the pool)
- Others differentiate down myeloid/erythroid/megakaryocyte lineages and produce mature blood cells
This is the moment engraftment is complete — the stem cell is no longer just surviving, it is actively making blood.
The Transplant Context
Engraftment is the same word used in bone marrow transplantation. When a patient receives donor HSCs intravenously, you wait for those cells to home to the marrow, settle in, and start producing blood cells. Clinically, engraftment is confirmed when the neutrophil count rises above 500 cells/µL — proof the new stem cells are working. Until that happens (~2 weeks post-transplant), the patient has essentially no immune system.
In EMH (Myelofibrosis)
The expelled HSCs do exactly the same thing in the spleen/liver — they home, lodge, and engraft in the latent fetal niches. The difference from normal transplant engraftment is that these are neoplastic HSCs, so the blood cells they produce are part of the malignant clone, and the process is uncontrolled.
In short: engraft = arrive + anchor + start working.
Ok
Got it. Let me know when you have another question.
This is a shared conversation. Sign in to Orris to start your own chat.